With peptide manufacturing and purification facilities in North Augusta, South Carolina supported by Shanghai, China, AmbioPharm has more than 600 chemists and professionals on staff. As a GMP peptide CDMO focused on superior quality, both facilities are regularly audited and inspected by the FDA.
Superior chemistry and facilities enable us to provide best-in-class quality with very reasonable costs of production.
More than 200 employees staff our U.S.- based-manufacturing facility, which also includes our Global Headquarters. The facilities are over 82,000 square feet of manufacturing space to meet our growing capacity requirements. The newest buildings include suites that increase our capacity for purification, lyophilization, and Quality Control in the U.S.
In March 2026, AmbioPharm announced a planned 68,000-square-foot expansion that will further strengthen our U.S. manufacturing footprint. Once completed, this purpose-built space will support full upstream commercial synthesis, flexible SPPS, LPPS, and hybrid synthesis, and large-scale, complex peptide programs, positioning the site to meet the needs of late-stage and commercial projects.
Take a virtual tour of our building.
In Shanghai, China, our commercial building has six additional large-scale manufacturing lines supporting out downstream manufacturing in North Augusta, South Carolina.
With expansion facilities in place, we will likely have one of the largest research and cGMP peptide manufacturing capacities worldwide. We can adapt our quality systems to interface with any size company or lab, including the largest commercial projects.
AmbioPharm can take partners from the inception and discovery phase of a project, including the R&D phase, all the way to commercial manufacturing with an emphasis on optimized process development. We utilize solid-phase, solution-phase (or liquid-phase), and/or hybrid peptide chemistry to produce the appropriate scale required by our clients during their project lifecycle.
For many years, development of peptide drugs by the pharmaceutical industry was shunned. Small molecule drugs were always more desirable than peptides. However, small molecule drugs rarely have the exquisite selectivity and quick onset of action that peptides have. Additionally, peptides are often cleared very quickly in vivo since their potency and quick onset require only very short half-lives.
Roche’s FuzeonTM (enfurvirtide) changed the scope of peptide development. The supply chain required to manufacture the metric ton quantities for this peptide API revolutionized peptide manufacturing.
Improvements in lowering the costs of the key Fmoc amino acids and other raw materials stimulated peptide development projects in numerous biotechnology and pharmaceutical companies worldwide. Additionally, improvements in production methods and delivery systems have resulted in a greatly enhanced portfolio of peptides which have either been approved as drugs or are currently under clinical evaluation.
AmbioPharm is growing along with the demand. As one of the world’s largest peptide capacity manufacturers, we are uniquely positioned to work with you.
SETTING A NEW STANDARD
Have a Peptide project?
